Background {#Sec1}
==========

During the past decade, advanced human epidermal growth factor receptor 2 (HER2)-targeted therapies have significantly improved outcomes for patients with HER2-positive advanced breast cancer (ABC) \[[@CR1]\]. Clinical evaluations of pertuzumab and trastuzumab (PT) in combination with different chemotherapy regimens in the CLEOPATRA trial and our previous study have highlighted clinical benefits \[[@CR2], [@CR3]\].

Pertuzumab and trastuzumab are humanized monoclonal anti-HER2 antibodies with complementary proposed mechanisms of action. Both antibodies work through the disruption of HER2 dimerization with HER3 and other epidermal growth factor receptors (EGFRs), leading to the inhibition of HER2 signaling \[[@CR4]\]. Anti-HER2 antibodies are thought to mediate tumor regression not only by interrupting oncogenic signaling, but also by inducing antibody-dependent cell-mediated cytotoxicity (ADCC) \[[@CR4]\]. ADCC can induce innate immune system responses via Fcγ receptors. These responses are sustained by natural killer (NK) cells; concomitantly, adaptive immunity involving tumor-infiltrating lymphocytes (TILs) develops in response to a specific antigen, which is sustained by T and B lymphocytes \[[@CR5]\]. The association of TILs with clinical outcomes suggests a significant role for antitumor immunity in HER2-positive ABC \[[@CR6]\].

Immune responses against cancer cells might involve a balance between tumor inhibitory mechanisms induced by intrinsic immunity and the ability of tumor cells to evade immune surveillance \[[@CR7]\]. During cancer immunoediting phases (i.e., elimination, equilibrium, and escape), activated effector cytotoxic T lymphocytes can migrate to the tumor and infiltrate the tumor microenvironment \[[@CR7], [@CR8]\]. It has been reported that circulating peripheral lymphocytes and neutrophils can migrate towards a tumor site in a directed manner along the humoral factors, such as a chemoattractant \[[@CR9]\]. A recent study demonstrated that circulating tumor-specific T lymphocytes related to neoantigens can be isolated from the peripheral blood of patients with melanoma \[[@CR10]\]. These data may indicate that blood-based parameters (PBBPs) reflect a local immune reaction against cancer cells. In line with such a mechanism, the absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) are reported to be immune-related prognostic factors for patients with malignancy \[[@CR11], [@CR12]\]. In addition, relationships between low levels of NLR and improved response to neoadjuvant chemotherapy have been reported for patients with breast cancer \[[@CR13]--[@CR15]\]. Therefore, PBBPs seem to affect treatment efficacy for ABC treated with chemotherapy and anti-HER2 therapy; however, this topic has yet to be fully studied.

In the present study, we aimed to explore whether PBBPs are related to improved progression-free survival (PFS) in patients with HER2-positive ABC treated with HER2-targeted PT combined with eribulin (ERI) or nab-paclitaxel (Nab-PTX).

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

### Patients {#Sec4}

Data from 51 patients included in two single-arm, phase 2 trials were included in this retrospective--prospective study (ERI + TP \[*N* = 30\] and Nab-PTX + TP \[*N* = 21\]) registered under University Hospital Medical Information Network (UMIN)000012375 and UMIN000006838, respectively, and approved by the ethics committee of The Cancer Institute Hospital of the Japanese Foundation for Cancer Research (\#2013--1096 and \#2017--1076) and the Hyogo College of Medicine (No. 1061 and No. 2720), respectively.

Drug dosing schedule in two prospective phase II studies {#Sec5}
--------------------------------------------------------

In the UMIN000006838 study, Nab-PTX 260 mg/m^2^ was administered intravenously over 30 min every 3 weeks. Two-step dose reductions to 220 mg/m^2^ and 180 mg/m^2^ were allowed before discontinuation was considered. Details of the dosing schedule in the UMIN000012375 study were published in our previous report \[[@CR3]\]. Dose reductions were allowed for both drugs but not for PT, whereas dose interruptions were allowed for all drugs. PT was administered according to a standard procedure as published previously \[[@CR3]\].

Evaluation of predictive factors {#Sec6}
--------------------------------

Data for PBBPs at baseline were obtained on the same day and just before the start of the first cycle of chemotherapy administration. No patient was administered granulocyte-colony stimulating factor at the last cycle of prior chemotherapy. Based on our study protocol, registration criteria required an interval of more than 3 weeks since a patient's last chemotherapy to minimize the influence of prior cytotoxic treatment. We evaluated ALC, NLR, and PLR data at baseline; the cutoff values for ALC, NLR, and PLR were set at 1000 or 1500 cells/μL, 2, and 150, respectively. Cutoff values for both NLR and PLR were defined as the median value of each parameter. The cutoff value for ALC was based on the previous study \[[@CR16]\].

Statistics {#Sec7}
----------

### PFS analysis {#Sec8}

PFS was defined as the time from treatment initiation to the date of disease progression or death; it was censored at the last adequate tumor assessment date before the cutoff date if no PFS event was observed prior to that time. PFS distributions were estimated using the Kaplan-Meier method.

### Univariate and multivariate analyses {#Sec9}

To evaluate the relationship between PFS and all clinical factors, univariate Cox proportional hazard regression models were used. Candidate predictive factors with a *P*-value less than 0.05 by univariate analysis were selected for evaluation by multivariate analysis. The value of ALC in terms of PFS was evaluated using a forest plot for each subgroup, dichotomized as \< 1500 and ≥ 1500 cells/μL.

We tested associations between ALC and baseline clinicopathological characteristics using the Wilcoxon rank sum test for continuous variables with two groups for age and previous chemotherapy regimens, and Fisher's exact test for other categorical variables, as shown in Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}. All statistical analyses were performed using JMP Pro 13 (SAS Institute Inc., Cary, NC, USA) and GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). *P* values of less than 0.05 were considered statistically significant.Table 1Demographics and baseline characteristics of patientsEribulin (*N* = 30)Nab-paclitaxel (*N* = 21)Total (*N* = 51)*P* valueMedian age(range)58 (31--76) yo58 (32--77) yo58 (31--77)0.5524Performance status010 (33%)20 (95%)30 (59%)\< 0.0001118 (60%)1 (5%)19 (37%)22 (7%)02 (4%)HER2 immunohistochemical staining3+25 (83%)15 (71%)40 (78%)0.3272+ (with FISH amplification)5 (17%)6 (19%)11 (22%)Estrogen receptorpositive14 (47%)9 (43%)23 (45%)1.000negative16 (53%)12 (57%)28 (55%)Progesterone receptorpositive5 (17%)6 (19%)11 (22%)0.327negative25 (83%)15 (71%)40 (78%)Metastatic sitesvisceral15 (50%)4 (19%)19 (37%)0.0389non-visceral15 (50%)17 (81%)32 (63%)Previous chemotherapy regimens, median(range)3.5 (1--9)1 (1--10)3 (1--10)0.0579

Results {#Sec10}
=======

Demographics and baseline clinical characteristics {#Sec11}
--------------------------------------------------

Table [1](#Tab1){ref-type="table"} shows a summary of the baseline clinical characteristics of patients from both studies and the differences between the ERI and Nab-PTX groups. A total of 51 patients (median age, 58 years) were enrolled; of these, 49 patients (96%) had favorable Eastern Cooperative Oncology Group Performance Status (ECOG-PS) scores of 0 or 1. Patients in the Nab-PTX group had significantly better ECOG-PS than those in the ERI group (*P* \< 0.0001). Forty patients (78%) had HER2 overexpression (3+) confirmed by immunohistochemistry (IHC), and 11 patients (22%) with IHC 2+ status were confirmed to be HER2 positive by fluorescence in situ hybridization. Twenty-three cases (45%) were estrogen receptor (ER) positive, whereas 11 patients (22%) were progesterone receptor (PgR) positive. Visceral metastases and non-visceral metastases were reported in 19 (37%) and 32 (63%) patients, respectively. Patients with visceral metastases (50%) were significantly more in the ERI group than in the Nab-PTX group (19%, *P* = 0.0389). Patients received a median of 3 (range, 1--10) prior treatments. There was no significant difference between groups in any parameters other than PS and metastatic sites.

Efficacy {#Sec12}
--------

### Anti-tumor activity {#Sec13}

All patients in the full-analysis set were evaluable for overall response rate (ORR). Investigator assessments identified 4 patients with complete response (8%), while 15 patients (29%) achieved partial response. The ORR was 37%, the disease control rate was 78% (*N* = 40), and the clinical benefit rate was 55% (*N* = 28). The median PFS was 301 days (95% confidence interval \[CI\]: 212--568) based on Kaplan--Meier estimates. There was no significant difference in PFS between ERI and Nab-PTX (hazard ratio \[HR\]: 1.593, 95% CI \[0.7510--3.378\], *P* = 0.2249).

### Univariate and multivariate analyses of PFS according to the baseline clinical factors {#Sec14}

Table [2](#Tab2){ref-type="table"} provides a summary of univariate and multivariate analyses of PFS according to baseline clinical characteristics. Univariate analysis showed that patients aged \< 58 years, those with ALC ≥1000/μL and ALC ≥1500/μL, and those with less than 3 lines of prior treatment had better PFS (Table [2](#Tab2){ref-type="table"}). Both NLR and PLR showed a trend toward statistical significance (Table [2](#Tab2){ref-type="table"}). ER and PgR positivity, HER2--3+, presence of visceral metastases, and treatment during study were not significant predictors of PFS (Table [2](#Tab2){ref-type="table"}).Table 2Univariate and multivariate analyses of progression-free survivalNumber of patientsUnivariateMultivariateParameterYesNoHR95% CIs*P* valueHR95% CIs*P* valueAge \< 58 yo23/5128/512.4401.120--5.3160.02480.3150.074--1.4670.1367Estrogen receptor positive (vs. negative)23/5128/511.1980.555--2.5880.6448Progesterone receptor positive (vs. negative)11/5140/511.1770.456--3.0400.7361HER2 3+40/5111/511.4210.558--3.6180.5431Non-visceral metastases (vs. visceral)32/5119/510.9260.429--1.9960.8441Eribulin (vs. Nab-PTX)30/5121/301.5930.751--3.3780.2249Prior treatment \< 3 line30/5121/300.4010.185--0.8700.02080.5280.234--1.1570.1106Absolute lymphocyte count ≥ 1000/uL37/5114/510.3080.133--0.7140.00610.7350.284--1.7700.4977Absolute lymphocyte count ≥ 1500/uL19/5132/510.3720.174--0.7960.01080.2960.098--0.7940.0150Neutrophil to lymphocyte ratio \> 231/5120/512.1090.985--4.5160.0548Platelet to lymphocyte ratio \> 15031/5120/512.0380.962--4.3180.0632

In the multivariate analysis, only ALC ≥1500/μL (HR: 0.296; 95% CI, 0.098--0794; *P* = 0.0150) was found to be correlated with PFS (Table [2](#Tab2){ref-type="table"}). PFS was also significantly longer in patients with ALC ≥1500/μL compared with 1000--1500/μL or \< 1000/μL (median PFS: not reached versus 363 versus 238 days, respectively; *P* = 0.0106; Fig. [1](#Fig1){ref-type="fig"}). An exploratory analysis (Fig. [2](#Fig2){ref-type="fig"}) of the HRs associated with ALC ≥1500/μL or \<  1500/μL consistently favored PFS in patients with ALC ≥1500/μL, irrespective of age (\< 58 and ≥ 58 years), HER2 levels (3+ and 2+), metastatic sites (visceral or non-visceral), and treatment (ERI or Nab-PTX), except in cases that were PgR-positive.Fig. 1Comparison of progression-free survival in patients according to absolute lymphocyte counts. Progression-free survival (PFS) was significantly longer in patients with absolute lymphocyte counts (ALC) ≥1500/μL (*P = 0.0106*). Solid lines indicate ALC ≥1500/μL, broken lines indicate ALC 1000--, \< 1500/μL, and dotted lines indicate ALC \< 1000/μL. Time (days) indicates the duration from the start of treatment to the occurrence of events. NR, not reachedFig. 2Forest plot showing hazard ratios for progression-free survival. The forest plots indicate the hazard ratios (HRs) and 95% confidence intervals (CIs) according to each factor. Evaluation of factors contributing to the prolongation of progression-free survival (PFS) with baseline clinical factors, stratified with absolute lymphocyte counts (ALC) ≥1500/μL

A comparison of baseline characteristics based on ALC ≥1500/μL is shown in Table [3](#Tab3){ref-type="table"}. There was no significant difference in the relationship between ALC levels and any factors, including metastatic site, number of prior treatments, or regimens.Table 3Comparison of baseline patients' characteristics based on patients with baseline absolute lymphocyte countsCharacteristicsAbsolute lymphocyte counts*P* value≥ 1500/μL (*n* = 19)\<  1500/μL (*n* = 32)Median age (range)58 (32--76) yo58 (31--77) yo0.7109Estrogen receptorPositive8 (42%)15 (47%)0.7787Negative11 (58%)17 (53%)Progesterone receptorPositive4 (21%)7 (22%)1.0000Negative15 (79%)25 (78%)HER23+12 (63%)28 (88%)0.07542+ FISH amplification7 (37%)4 (12%)Visceral metastases5 (26%)14 (47%)0.2465Non-visceral metastases14 (74%)18 (56%)Prior treatment\<  3 lines13 (68%)17 (53%)0.3808≥ 3 lines6 (32%)15 (47%)Combination chemotherapy with trastuzumab plus pertuzumabEribulin8 (42%)22 (69%)0.0815Nab-paclitaxel11 (58%)10 (31%)

Discussion {#Sec15}
==========

In this prospective-retrospective evaluation of PBBPs in baseline clinical data, we identified ALC as a predictive factor for PFS in patients with HER2-positive ABC. Additionally, high ALC at baseline was significantly associated with improved PFS in HER2-positive ABC treated with either ERI or Nab-PTX in combination with PT. To the best of our knowledge, this study is the first to analyze predictive factors associated with ALC in HER2-positive ABC. For treatment of ABC, predictive factors related to systemic immune response are yet to be considered in clinical practice.

Usually, somatic mutations in cancer cells lead to the production of altered proteins that are recognized as antigens by the innate immune system via major histocompatibility complex class I; consequently, TILs inhibit tumor progression \[[@CR17]\]. Anti-HER2 antibodies also mediate anticancer effects in part via the induction of ADCC by opsonizing cancer cells that are recognized by the innate immune system \[[@CR18]\]. Anti-HER2 antibodies not only neutralize the trophic function of HER2, but they also elicit an initial NK-mediated ADCC response that is presumably followed by a cytotoxic T lymphocyte-dependent adaptive immune repose directed against breast cancer associated antigens \[[@CR18]\]. The effect of pertuzumab in antitumor immunity is still unknown. In a subgroup analysis of the CLEOPATRA trial, patients with a high abundance of TILs (\> 20%) had better PFS than those with low TILs (≤20%) in the PT group, but not in the trastuzumab group \[[@CR6]\]. These data might indicate that preexisting immune responses enhance treatment efficacy, which could be boosted by combination therapy with conventional chemotherapy and PT \[[@CR19]\]. Although prognostic markers including NLR and PLR have been evaluated in several malignant diseases \[[@CR12]\], our study demonstrated that ALC is superior to NLR and PLR for predicting improved PFS in ABC patients treated with conventional chemotherapy combined with PT. High ALC may indicate enhanced immunity in tumors; alternatively, ALC may be a potential biomarker of host immunity. Although the detailed underlying mechanism of prolonged PFS in patients with ALC ≥1500/μL is currently unknown, it is likely that these results reflect the synergistic activity of PT acting alongside the host immune response.

Our results showed that the favorable PFS in patients with ALC ≥1500/μL was prominent in the ER- and PgR- subgroups. It is well established that TILs are not frequently observed in ER+/HER2- breast cancers \[[@CR20]\]; thus, the prognostic significance of TILs is not recognized in these cases \[[@CR20]\]. Even among HER2+ breast cancers, the frequency of TILs was significantly lower in ER+ cases compared with ER- cases \[[@CR6]\]. These data indicate that anticancer immunity is not dominant in ER+ cases. Thus, ALC may be a less effective predictor in ER+ and PgR+ cases compared to ER- and PgR- cases.

Both ERI and Nab-PTX could be classified as microtubule inhibitors with differential mechanisms of action \[[@CR21]\]. Both drugs can cause G2/M cell cycle arrest due to disruption of mitotic spindles, resulting in apoptotic cell death after prolonged mitotic blockage \[[@CR22]\]. In the current study, a favorable PFS in patients with ALC ≥1500/μL was observed, irrespective of a combination treatment with ERI or Nab-PTX. Because chemotherapies differ with regard to immunogenicity (e.g., immunogenic \[doxorubicin or cyclophosphamide\] or non-immunogenic \[dacarbazine\] \[[@CR21]\]), it is unclear whether relationships exist between PFS and ALC in patients treated with PT in combination with other chemotherapies or endocrine therapies.

This study has several limitations. First, we used a retrospective design from two single prospective phase 2 studies with relatively small sample sizes. Second, prior chemotherapies may affect baseline levels of PBBPs. However, because a positive association between ALC levels and PFS was consistently recognized in patients with and without prior chemotherapy, the influence of prior chemotherapy appears to be limited. There was no significant difference for any PBBP during the course of treatment (data not shown), but the prognostic significance of PBBPs during the treatment course is currently unknown. Considering these limitations, prospective studies that include a large number of patients are needed to further elucidate the results of the present study.

Conclusions {#Sec16}
===========

Our findings strongly suggest that ALC at baseline is a useful predictor for prolonged PFS in HER2-positive ABC patients treated with PT in combination with ERI or Nab-PTX. Baseline ALC may be indicative of pre-existing anti-tumor host immunity or the potential immune response following PT-based therapy. Future research might focus on the baseline systemic immune response evaluable by ALC in daily clinical practice.
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